The Hunt for the Next 10 Bagger

[BioSpecialist]

RDHL the next big higherflyer in the bio sector

RedHill Biopharma's RHB-104: A Potential Game Changer for Crohn's Disease?
http://www.bionapcfa.com/2015/10/redhill-biopharmas-rhb-104-potential.html

The opportunity for RedHill Biopharma with RHB-104 looks significant. If the Phase 3 trial is successful, I think the market will start to view RHB-104 as having peak sales in the $500-750 million range for the U.S., with potential expansion to over one billion on a global basis.
------

Dan Suesskind , Director
Mr. Suesskind, who served 31 years as CFO of Teva Pharmaceutical Industries (NYSE: TEVA) until 2008, had played a pivotal role in the strategic activities of the Israeli generic pharmaceuticals giant, including the acquisition of more than 30 companies. During that period, Teva grew from a small Israeli company with a market cap of $37 million, into a leading global company with a market cap exceeding $34 billion in 2008. Mr. Suesskind was a member of Teva’s board of directors until recently.